Protein Design Labs, Inc. (PDL) has announced that Samuel Broder, M.D., has been elected to the company's Board of Directors.
Dr. Broder is a physician- scientist with special expertise in the relationship between disorders of the immune system and cancer.
“We are delighted to welcome Sam to the PDL Board and are certain his expertise in pharmaceutical research and development will be a major asset to the company during this phase of growth,” said Mark McDade, Chief Executive Officer, PDL.
“We have six products entering later-stage clinical trials. Dr. Broder's background in clinical development will be invaluable as we aim to commercialize these therapies for a range of serious medical conditions.”
Dr. Broder has been Chief Medical Officer of Celera Genomics since joining that company in 1998.
He has broad responsibilities for medical affairs, including the integration of genomic, biological and medical information.
Dr. Broder began his research career in the Metabolism Branch of the National Cancer Institute (NCI) in 1972.
Following the onset of the AIDS epidemic, Dr. Broder's laboratory added studies of anti-retroviral agents to its research repertoire and made significant contributions to the development of AIDS drugs such as AZT ddl and ddC.
In 1989, President Ronald Reagan named Dr. Broder Director of the NCI. Under his leadership, the NCI initiated a number of important large-scale human trials in the prevention, diagnosis, and treatment of cancer.
In the spring of 1995, Dr. Broder became Senior Vice President for Research and Development at the IVAX Corporation (now in process of being acquired by TEVA Pharmaceutical Industries, Ltd.) in Florida, where he directed a broad range of pharmaceutical research on new drugs for heart disease, diabetes and diseases of the lung.
Dr. Broder received his bachelor's and medical degrees from the University of Michigan. He is a member of the Institute of Medicine of the U.S. National Academy of Sciences, is the author of 300 scholarly papers and holds numerous patents.